Focus on Diabetes
About This Show
ReachMD takes an in-depth look at diabetes, a disease identified in nearly 1 in 10 Americans, which upsets the lives of millions more. Even more disturbing, the rates of new cases of diagnosed diabetes have risen almost twofold during the past decade. Nutrition, exercise and genetics are all factors in how the disease affects children, adults and the elderly, but that's only the beginning. How are surgical options changing the way we think about the disease? How close are we to a cure for Type 1 diabetes? Are there treatment lessons we can take from community-based initiatives abroad? Tune in to gain insights for your practice.
Most Recent Episode
FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin
Based on new data from two large clinical trials, the FDA concluded that the type 2 diabetes medicine canagliflozin (brand names Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. The FDA is requiring new warnings, including their most prominent Boxed Warning, be added to the canagliflozin drug labels to describe this risk. Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs. Report side effects involving canagliflozin and other medicines to the FDA MedWatch program at fda.gov/medwatch. A link to the full communication detailing specific information for health care professionals and the complete Data Summary can be found at fda.gov/DrugSafetyCommunications. If you have drug questions, contact the FDA at email@example.com.